Thermo Fisher Scientific’s pharmaceutical services business has won a number of contracts to help its customers move production from Europe or Asia to the U.S., the medical equipment maker’s CEO, Marc Casper, said on Tuesday.
“There’s a very big focus on reshoring more production and activity to the U.S.,” Casper said at the J.P. Morgan Healthcare Conference, adding that the trend is going to be a tailwind in 2027 and 2028.
Sign up here.
U.S. President Donald Trump has pu… [735 chars]
Source: Reuters | Published: 2026-01-13T18:27:18Z
Credit: Reuters
